Product Description
Mechanisms of Action: AKR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Polyneuropathies
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JapicCTI-142715 | P1 |
Completed |
Unknown |
2016-06-01 |
|
JapicCTI-142753 | P1 |
Completed |
Unknown |
2015-11-01 |
|
2008-002843-18 | P3 |
Completed |
Unknown |
2013-01-10 |
|
AS3201-G000-291 | P3 |
Completed |
Polyneuropathies |
2013-01-01 |
60% |